<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183350</url>
  </required_header>
  <id_info>
    <org_study_id>1218.2</org_study_id>
    <nct_id>NCT02183350</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (1, 2.5, 5, 10 and 25 mg q.d. for 12 Days) of BI 1356 BS as Powder in the Bottle (PIB) in Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study was to investigate the safety and tolerability of
      BI 1356 BS following administration of multiple rising oral doses of 1 mg, 2.5 mg, 5 mg, and
      10 mg over 12 days in male patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal changes in Vital signs (blood pressure (BP), pulse rate (PR))</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal changes in 12-lead ECG (electrocardiogram)</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum concentration)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the concentration-time curve of the analyte in plasma)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae (amount of analyte that is eliminated in urine)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe (fraction of analyte excreted in urine)</measure>
    <time_frame>up to 288 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR (renal clearance of the analyte in plasma)</measure>
    <time_frame>up to 288 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (terminal rate constant in plasma at steady state)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life of the analyte in plasma at steady state)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time of the analyte in the body after 12 administrations at steady state)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state)</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PTF (peak trough fluctuation)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax based on Cmax</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC based on AUCτ</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma</measure>
    <time_frame>predose, up to 456 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose levels</measure>
    <time_frame>up to 13 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 1356 BS - single rising dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356 BS - single rising dose</intervention_name>
    <arm_group_label>BI 1356 BS - single rising dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male patients with proven diagnose of type 2 diabetes mellitus treated with diet and
        exercise only or with one (or two) oral hypoglycaemic agents besides glitazones

          -  Glycosylated haemoglobin A1 (HbA1c)

               -  ≤ 8.5 % at screening for patients treated with diet and exercise and/or one oral
                  hypoglycaemic agent or

               -  ≤ 8.0 % at screening for patients treated with two oral hypoglycaemic agents

          -  Age ≥21 and Age ≤65 years

          -  BMI ≥18.5 and BMI ≤35 kg/m2 (Body Mass Index)

          -  Caucasian ethnicity

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice GCP and the local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR)
             and Electrocardiogram (ECG)) deviating from normal and of not acceptable clinical
             relevance

          -  Clinically relevant concomitant diseases like renal insufficiency, cardiac
             insufficiency New York Heart Association (NYHA) II-IV, known cardiovascular diseases
             including hypertension &gt; 160/110 mmHg, stroke and Transient ischaemic attack (TIA)

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia and
             medically treated hypertension

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             relevant neurological disorders besides polyneuropathy

          -  Chronic or relevant acute infections (e.g. Human immunodeficiency virus (HIV),
             Hepatitis)

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial
             except allowed co-medication

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (more than 60 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of not acceptable clinical
             relevance

          -  Change of drug dosing of allowed co-medication (anti-hypertensive agents, acetylic
             salicylic acid and statins) within the last 3 months

          -  Any ECG value outside of the reference range and of clinical relevance including, but
             not limited to QRS interval &gt; 120 ms or QTcB &gt; 450 ms or QT &gt;500 ms

          -  Fasted blood glucose &gt; 240 mg/dl (=13.3 mmol/L) on two consecutive days during washout

          -  Serum creatinine above upper limit of normal at screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

